Literature DB >> 28029545

Highly sensitive LC-MS/MS methods for urinary biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and methotrexate antineoplastic drugs and routine application.

Mireille Canal-Raffin1, Karim Khennoufa2, Béatrice Martinez3, Yves Goujon4, Celia Folch5, Dominique Ducint2, Karine Titier2, Patrick Brochard6, Catherine Verdun-Esquer7, Mathieu Molimard8.   

Abstract

Highly sensitive ESI-LC-MS/MS methods were developed for urinary biological monitoring of occupational exposure to cyclophosphamide (CP), ifosfamide (IF), and methotrexate (MTX), which are hazardous antineoplastic drugs frequently handled by healthcare professionals. Extraction methods consisted of liquid/liquid extraction for simultaneous urinary CP and IF assays, and of solid phase extraction for the urinary MTX assay. A good linearity (r2>0.997), precision (CV<14.6%), and accuracy (bias<9.9%) were achieved for all compounds. The limit of detection (LOD) was 10pg/ml and the lower limit of quantification (LOQ) was 20pg/ml for all three drugs. Applying these methods in routine, more than 116 healthcare professionals occupationally exposed to antineoplastic drugs were monitored and 635 urines were analysed. Eleven healthcare professionals (9.5%) were found to be contaminated to at least one of the three antineoplastic drugs. Among analysed urines, 22 samples were found positives. The measured concentrations ranged from 20.1 to 1850pg/ml and, for six samples, concentrations were at CP trace level, between the LOD and LOQ values (10-20pg/ml). Such efficient analytical tools combining high specificity with high sensitivity are essential for reliable detection and routine biological monitoring of healthcare professionals occupationally exposed to these widely used antineoplastic drugs. These methods allow to monitor the healthcare professionals exposure to antineoplastic drugs in the aim to assess the effectiveness of collective and individual protective measures.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antineoplastic drugs; Biological monitoring; Healthcare professionals; LC–MS/MS; Occupational exposure; Urine

Year:  2016        PMID: 28029545     DOI: 10.1016/j.jchromb.2016.10.021

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers.

Authors:  Pan Shu; Ting Zhao; Bo Wen; Kari Mendelsohn-Victor; Duxin Sun; Christopher R Friese; Manjunath P Pai
Journal:  J Oncol Pharm Pract       Date:  2019-09-04       Impact factor: 1.809

Review 2.  A review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workers.

Authors:  Patricia I Mathias; Thomas H Connor; Clayton B'Hymer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-06-19       Impact factor: 3.205

Review 3.  Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples.

Authors:  Forough Karami; Sara Ranjbar; Younes Ghasemi; Manica Negahdaripour
Journal:  J Pharm Anal       Date:  2019-06-20

4.  Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study.

Authors:  Antoine Villa; Mathieu Molimard; Emmanuelle Bignon; Béatrice Martinez; Magali Rouyer; Simone Mathoulin-Pelissier; Isabelle Baldi; Catherine Verdun-Esquer; Mireille Canal-Raffin
Journal:  BMJ Open       Date:  2019-11-10       Impact factor: 2.692

Review 5.  Exposure to Antineoplastic Drugs in Occupational Settings: A Systematic Review of Biological Monitoring Data.

Authors:  Veruscka Leso; Cristina Sottani; Carolina Santocono; Francesco Russo; Elena Grignani; Ivo Iavicoli
Journal:  Int J Environ Res Public Health       Date:  2022-03-21       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.